Market closedNon-fractional
Intra-Cellular Therapies/ITCI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Intra-Cellular Therapies
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Ticker
ITCI
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
New York, United States
Employees
610
ITCI Metrics
BasicAdvanced
$8.5B
Market cap
-
P/E ratio
-$1.16
EPS
1.01
Beta
-
Dividend rate
Price and volume
Market cap
$8.5B
Beta
1.01
Financial strength
Current ratio
5.123
Quick ratio
4.501
Long term debt to equity
2.125
Total debt to equity
2.732
Management effectiveness
Return on assets (TTM)
-11.23%
Return on equity (TTM)
-18.07%
Valuation
Price to revenue (TTM)
15.15
Price to book
13.09
Price to tangible book (TTM)
13.09
Price to free cash flow (TTM)
-79.034
Growth
Revenue change (TTM)
65.45%
Earnings per share change (TTM)
-52.01%
3-year revenue growth (CAGR)
139.08%
3-year earnings per share growth (CAGR)
-28.21%
What the Analysts think about ITCI
Analyst Ratings
Majority rating from 17 analysts.
ITCI Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$145M
9.70%
Net income
-$15M
-46.67%
Profit margin
-10.49%
-51.41%
ITCI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.45
-$0.25
-$0.30
-$0.16
-
Expected
-$0.59
-$0.57
-$0.44
-$0.32
-$0.18
Surprise
-23.75%
-55.83%
-32.23%
-49.61%
-
ITCI News
AllArticlesVideos
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
GlobeNewsWire·3 days ago
Intra-Cellular Brightens MDD Outlook With Caplyta Success
Seeking Alpha·1 month ago
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Intra-Cellular Therapies stock?
Intra-Cellular Therapies (ITCI) has a market cap of $8.5B as of July 27, 2024.
What is the P/E ratio for Intra-Cellular Therapies stock?
The price to earnings (P/E) ratio for Intra-Cellular Therapies (ITCI) stock is 0 as of July 27, 2024.
Does Intra-Cellular Therapies stock pay dividends?
No, Intra-Cellular Therapies (ITCI) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Intra-Cellular Therapies dividend payment date?
Intra-Cellular Therapies (ITCI) stock does not pay dividends to its shareholders.
What is the beta indicator for Intra-Cellular Therapies?
Intra-Cellular Therapies (ITCI) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Intra-Cellular Therapies stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.